New York, New York–(Newsfile Corp. – December 30, 2024) – WHY: The Rosen Law Firm, a global investor rights law firm, announces that a shareholder has filed a class action lawsuit on behalf of purchasers of securities of Caribou Biosciences, Inc. (NASDAQ: CRBU) between July 14, 2023 and July 17, 2024, both dates inclusive (“Teaching Period”). A class action lawsuit has already been filed. If you want to be the chief prosecutor, you have to move the court no later than February 24, 2025.
SO WHAT: If you purchased securities of Caribou Biosciences during the Exchange Period, you may be entitled to compensation without paying any fees or out-of-pocket expenses through a contingency fee arrangement.
WHAT TO DO NEXT: To join the Caribou Biosciences class action lawsuit, go to https://rosenlegal.com/submit-form/?case_id=11988 or call Phillip Kim, Esq. toll free at 866-767-3653 or email case@rosenlegal.com for information about the class action. A class action lawsuit has already been filed. If you want to be the chief prosecutor, you have to move the court no later than February 24, 2025. The lead plaintiff is the representative party that acts on behalf of the other class members in the conduct of the litigation.
WHY ROSEN’S LAW: We encourage investors to choose a qualified advisor with experience in successful leadership roles. Often the firms issuing the notices do not have comparable experience, resources or any significant recognition from their peers. Be wise in choosing an advisor. The Rosen Law Firm represents investors worldwide, concentrating its practice in securities class actions and equity derivative litigation. The Rosen Law Firm secured the largest securities class action settlement to date against a Chinese company at the time. The Rosen Law Firm is ranked #1 by ISS Securities Class Action (WA:) Services for numerous securities class action settlements in 2017. The firm has been ranked in the top 4 every year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone, the company secured more than $438 million for investors. In 2020, founding partner Laurence Rosen was named a Law360 Claimant Bar Association Titan. Many of the firm’s lawyers have been recognized by Lawdragon and Super Lawyers.
CASE DETAILS: According to the lawsuit, the statements made during the Lecture Period were false and/or materially misleading because (1) the defendants overstated the safety, efficacy, and durability of CB-010 relative to approved autologous CAR-T cell therapies in the treatment of sr/r B -NHL patients and/or LBCL, as well as the overall clinical results and commercial prospects of CB-010; (2) Caribou was exposed to a significant risk of not having sufficient cash, liquidity and/or other capital to fund its ongoing business operations, including preclinical research activities related to the allogeneic CAR-NK platform; (3) the foregoing is likely to have had a material adverse effect on Caribou’s business and operations; and (4) as a result, the defendants’ public statements were materially false and misleading at all relevant times. When the true details came to market, the lawsuit alleges, investors suffered damages.
To join the Caribou Biosciences class action lawsuit, go to https://rosenlegal.com/submit-form/?case_id=11988, call Phillip Kim, Esq. toll free at 866-767-3653 or email case@rosenlegal.com for information about the class action.
No class is certified. Until the class is certified, you will not be represented by an attorney unless you retain one. You can choose a lawyer of your choice. You can also remain an absent member of the class and do nothing at this time. An investor’s ability to participate in a potential future recovery does not depend on whether it is the lead plaintiff.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook (NASDAQ:): https:/ /www.facebook.com/rosenlawfirm/.
Advertising of lawyers. Previous results do not guarantee a similar outcome.
——————————–
To view the original version of this press release, visit https://www.newsfilecorp.com/release/235569
